Results 31 to 40 of about 11,328,563 (174)

Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review

Frontiers in Neurology, 2023
BackgroundCerebral amyloid angiopathy-related inflammation (CAA-ri) is a clinical syndrome characterized by MRI findings of amyloid-related imaging abnormalities-edema (ARIA-E) suggestive of autoimmune and inflammatory reaction and hemorrhagic evidence ...
Jhih-Yong Yang, Yung-Tsai Chu, Hsin-Hsi Tsai, Hsin-Hsi Tsai, Jiann-Shing Jeng   +4 more
doaj   +1 more source

Donanemab Infusion and Recurrent Seizures in a Patient With Alzheimer's Disease and Epilepsy in the Absence of Amyloid-Related Imaging Abnormalities (ARIA). [PDF]

Cureus
Espinosa PS, Li S, Preisler J, Hennekens CH.   +3 more
europepmc   +2 more sources

Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report

Radiology Case Reports, 2023
Patients with Alzheimer's disease who have been given monoclonal antibodies targeting amyloid-β (Aβ) (eg, gantenerumab, donanemab, lecanemab, and aducanumab) for scientific purposes may have a spectrum of imaging findings known as amyloid-related imaging
Houman Sotoudeh, MD, Mohammadreza Alizadeh, MD, Ramin Shahidi, MD, Parnian Shobeiri, MD, MPH, Natelson love, MD, Aparna Singhal, MD   +5 more
doaj   +1 more source

Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA

, 2023
Anti-amyloid therapies (AATs), such as anti-amyloid monoclonal antibodies, are emerging treatments for people with early Alzheimer’s disease (AD). AATs target amyloid β plaques in the brain.
Nho, Kwangsik, Edward Zamrini, Kwangsik Nho, Ihab Hajjar, Zamrini, Edward, Mo-Kyung Sin, Sin, Mo-Kyung, Ahmed, Ali, Hajjar, Ihab, Ali Ahmed   +9 more
core   +1 more source

Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti–β-Amyloid Immunotherapy

, 2022
Background and objectives: To assess the incidence of amyloid-related imaging abnormalities (ARIA) in clinical trials of anti-β-amyloid (Aβ) immunotherapy and compare the incidence among different agents and clinical characteristics to identify possible ...
So Yeong Jeong, Jae-Hong Lee, Sang Joon Kim, Jae-Sung Lim, Chong Hyun Suh, Woo Hyun Shim   +5 more
core   +1 more source

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab [PDF]

, 2018
OBJECTIVE: To evaluate whether amyloid-related imaging abnormalities with edema/effusion (ARIA-E) observed in bapineuzumab clinical trials was associated with specific biomarker patterns.
Sperling, R, Novak, G, Brashear, HR, Scheltens, P, Wang, D, Blennow, K, Schmidt, ME, ELN115727-301/302 Investigator Group, Liu, E, Fox, NC, Ketter, N, Einstein, S, Salloway, S, Booth, K, Streffer, J   +14 more
core   +3 more sources

Symptomatic amyloid-related imaging abnormalities after Lecanemab treatment in an APOE ε4 homozygous patient with mild cognitive impairment due to Alzheimer's disease: one case report

Chinese Journal of Contemporary Neurology and Neurosurgery
Objective To report a case of symptomatic amyloid-related imaging abnormalities (ARIA) following Lecanemab treatment in patient with mild cognitive impairment due to Alzheimer's disease (AD-MCI), so as to provide references for the clinical safe ...
CAO Wen-wei, GENG Jie-li, JI Chen-hui, SUN Wei-feng, SUN Ya-wen, WANG Gang   +5 more
doaj   +1 more source

Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice [PDF]

, 2022
Monoclonal antibodies are emerging disease-modifying therapies for Alzheimer disease that require brain MR imaging for eligibility assessment as well as for monitoring for amyloid-related imaging abnormalities.
Ramanan, VK, Cogswell, PM, Benzinger, TS, Jack, CR, Whitlow, CT, Barkhof, F, Raji, CA, Poussaint, TY, Barakos, JA   +8 more
core   +1 more source

Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease [PDF]

, 2022
OBJECTIVE: To determine the characteristics of participants with amyloid-related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD).
Holdridge, Karen C, Masellis, Mario, Mummery, Catherine J, Aggarwal, Neelum T, Wojtowicz, Jakub, Jack, Clifford R, Fox, Nick C, Bateman, Randall J, Wang, Qing, Snider, B Joy, Chhatwal, Jasmeer P, Preboske, Gregory M, Cruchaga, Carlos, Borowski, Bret, Jimenez-Velazquez, Ivonne Z, Black, Sandra E, Wallon, David, Gordon, Brian A, Ringman, John M, Levin, Johannes, Benzinger, Tammie LS, McCullough, Austin A, Shimada, Hiroyuki, Chen, Charles D, Park, Ethan, McDade, Eric, Gauthier, Serge, Flores, Shaney, Llibre-Guerra, Jorge J, Xiong, Chengjie, Klein, Gregory, Wang, Guoqiao, Hobbs, Diana A, Hassenstab, Jason, Hofmann, Carsten, Li, Yan, Bird, Thomas D, Jucker, Mathias, Mancini, Michele, Suzuki, Kazushi, Dominantly Inherited Alzheimer Network Trials Unit., Joseph-Mathurin, Nelly, Berman, Sarah B, Clifford, David B, Perrin, Richard J, Hornbeck, Russ C, Hsiung, Ging-Yuek R, Yaari, Roy, Brooks, William S, McKay, Nicole S, Salloway, Stephen P, Fagan, Anne M, Honig, Lawrence S, Farlow, Martin, Clarnette, Roger   +54 more
core   +1 more source

Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment

Pharmaceuticals
Background: Anti-amyloid therapies (AAT) are reshaping the therapeutic landscape of Alzheimer’s disease (AD), yet their implementation remains constrained by the risk of amyloid-related imaging abnormalities (ARIA).
Marialuisa Zedde, Mattia Losa, Andrea Donniaquio, Ilaria Gandoglia, Massimo Del Sette, Luca Roccatagliata, Fabrizio Piazza, Matteo Pardini, Rosario Pascarella   +8 more
doaj   +1 more source